Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment.

Journal of Crohn's & colitis

Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, Coles AJ, Silverberg MS, Irving PM, Chung-Faye G, Silber E, Cummings JRF, Lytvyak E, Andersen V, Wood AR, Tyrrell J, Beaumont RN, Weedon MN, Kennedy NA, Spiers A, Harrower T, Goodhand JR, Ahmad T.
PMID: 32497177
J Crohns Colitis. 2020 Dec 02;14(12):1653-1661. doi: 10.1093/ecco-jcc/jjaa104.

BACKGROUND: Anti-TNF exposure has been linked to demyelination events. We sought to describe the clinical features of demyelination events following anti-TNF treatment and to test whether affected patients were genetically predisposed to multiple sclerosis [MS].METHODS: We conducted a case-control...

Cite
Lin S, Green HD, Hendy P, et al. Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. J Crohns Colitis. 2020;14(12):1653-1661doi: 10.1093/ecco-jcc/jjaa104.
Lin, S., Green, H. D., Hendy, P., Heerasing, N. M., Chanchlani, N., Hamilton, B., Walker, G. J., Heap, G. A., Hobart, J., Martin, R. J., Coles, A. J., Silverberg, M. S., Irving, P. M., Chung-Faye, G., Silber, E., Cummings, J. R. F., Lytvyak, E., Andersen, V., Wood, A. R., Tyrrell, J., Beaumont, R. N., Weedon, M. N., Kennedy, N. A., Spiers, A., Harrower, T., Goodhand, J. R., & Ahmad, T. (2020). Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. Journal of Crohn's & colitis, 14(12), 1653-1661. https://doi.org/10.1093/ecco-jcc/jjaa104
Lin, Simeng, et al. "Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment." Journal of Crohn's & colitis vol. 14,12 (2020): 1653-1661. doi: https://doi.org/10.1093/ecco-jcc/jjaa104
Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, Coles AJ, Silverberg MS, Irving PM, Chung-Faye G, Silber E, Cummings JRF, Lytvyak E, Andersen V, Wood AR, Tyrrell J, Beaumont RN, Weedon MN, Kennedy NA, Spiers A, Harrower T, Goodhand JR, Ahmad T. Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. J Crohns Colitis. 2020 Dec 02;14(12):1653-1661. doi: 10.1093/ecco-jcc/jjaa104. PMID: 32497177.
Copy Download .nbib Format: NLM
Sleep Faster! (Somebody else needs your blanket...).

Australian health review : a publication of the Australian Hospital Association

Anstey MH, Gildfind SP, Litvak E.
PMID: 22935109
Aust Health Rev. 2012 Aug;36(3):244-7. doi: 10.1071/AH11063.

One of the elements of the health reform plan, as agreed to by Australian state and federal governments, is to introduce a 4-h National Access Target, to reduce emergency department (ED) waiting times. This article highlights the flawed rationale...

Cite
Anstey MH, Gildfind SP, Litvak E. Sleep Faster! (Somebody else needs your blanket...). Aust Health Rev. 2012;36(3):244-7doi: 10.1071/AH11063.
Anstey, M. H., Gildfind, S. P., & Litvak, E. (2012). Sleep Faster! (Somebody else needs your blanket...). Australian health review : a publication of the Australian Hospital Association, 36(3), 244-7. https://doi.org/10.1071/AH11063
Anstey, Matthew H R, et al. "Sleep Faster! (Somebody else needs your blanket...)." Australian health review : a publication of the Australian Hospital Association vol. 36,3 (2012): 244-7. doi: https://doi.org/10.1071/AH11063
Anstey MH, Gildfind SP, Litvak E. Sleep Faster! (Somebody else needs your blanket...). Aust Health Rev. 2012 Aug;36(3):244-7. doi: 10.1071/AH11063. PMID: 22935109.
Copy Download .nbib Format: NLM
Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis.

Canadian liver journal

Lytvyak E, Hosamani I, Montano-Loza AJ, Saxinger L, Mason AL.
PMID: 33981960
Can Liver J. 2019;2(1):31-44. doi: 10.3138/canlivj.2018-0020. Epub 2019 Jan 09.

BACKGROUND: Prior studies using reverse transcriptase inhibitors to treat a human betaretrovirus (HBRV) in patients with primary biliary cholangitis (PBC) resulted in a 21% reduction in alkaline phosphatase (ALP). Herein, we studied the safety and efficacy of combination tenofovir-emtricitabine...

Cite
Lytvyak E, Hosamani I, Montano-Loza AJ, et al. Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. Can Liver J. 2019;2(1):31-44doi: 10.3138/canlivj.2018-0020.
Lytvyak, E., Hosamani, I., Montano-Loza, A. J., Saxinger, L., & Mason, A. L. (2019). Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. Canadian liver journal, 2(1), 31-44. https://doi.org/10.3138/canlivj.2018-0020
Lytvyak, Ellina, et al. "Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis." Canadian liver journal vol. 2,1 (2019): 31-44. doi: https://doi.org/10.3138/canlivj.2018-0020
Lytvyak E, Hosamani I, Montano-Loza AJ, Saxinger L, Mason AL. Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. Can Liver J. 2019;2(1):31-44. doi: 10.3138/canlivj.2018-0020. Epub 2019 Jan 09. PMID: 33981960; PMCID: PMC8112609.
Copy Download .nbib Format: NLM
Energy Transport of Hybrid Charge-Transfer Excitons.

ACS nano

Cheng CH, Cordovilla Leon D, Li Z, Litvak E, Deotare PB.
PMID: 32806037
ACS Nano. 2020 Aug 25;14(8):10462-10470. doi: 10.1021/acsnano.0c04367. Epub 2020 Aug 10.

We investigate the energy transport in an organic-inorganic hybrid platform formed between semiconductors that support stable room-temperature excitons. We find that following photoexcitation, fast-moving hot hybrid charge-transfer excitons (HCTEs) are formed in about 36 ps

Cite
Cheng CH, Cordovilla Leon D, Li Z, et al. Energy Transport of Hybrid Charge-Transfer Excitons. ACS Nano. 2020;14(8):10462-10470doi: 10.1021/acsnano.0c04367.
Cheng, C. H., Cordovilla Leon, D., Li, Z., Litvak, E., & Deotare, P. B. (2020). Energy Transport of Hybrid Charge-Transfer Excitons. ACS nano, 14(8), 10462-10470. https://doi.org/10.1021/acsnano.0c04367
Cheng, Che-Hsuan, et al. "Energy Transport of Hybrid Charge-Transfer Excitons." ACS nano vol. 14,8 (2020): 10462-10470. doi: https://doi.org/10.1021/acsnano.0c04367
Cheng CH, Cordovilla Leon D, Li Z, Litvak E, Deotare PB. Energy Transport of Hybrid Charge-Transfer Excitons. ACS Nano. 2020 Aug 25;14(8):10462-10470. doi: 10.1021/acsnano.0c04367. Epub 2020 Aug 10. PMID: 32806037.
Copy Download .nbib Format: NLM
The Right Kind of Pooled Testing for the Novel Coronavirus: First, Do No Harm.

American journal of public health

Litvak E, Dentzer S, Pagano M.
PMID: 32970452
Am J Public Health. 2020 Dec;110(12):1772-1773. doi: 10.2105/AJPH.2020.305945. Epub 2020 Sep 24.

No abstract available.

Cite
Litvak E, Dentzer S, Pagano M. The Right Kind of Pooled Testing for the Novel Coronavirus: First, Do No Harm. Am J Public Health. 2020;110(12):1772-1773doi: 10.2105/AJPH.2020.305945.
Litvak, E., Dentzer, S., & Pagano, M. (2020). The Right Kind of Pooled Testing for the Novel Coronavirus: First, Do No Harm. American journal of public health, 110(12), 1772-1773. https://doi.org/10.2105/AJPH.2020.305945
Litvak, Eugene, et al. "The Right Kind of Pooled Testing for the Novel Coronavirus: First, Do No Harm." American journal of public health vol. 110,12 (2020): 1772-1773. doi: https://doi.org/10.2105/AJPH.2020.305945
Litvak E, Dentzer S, Pagano M. The Right Kind of Pooled Testing for the Novel Coronavirus: First, Do No Harm. Am J Public Health. 2020 Dec;110(12):1772-1773. doi: 10.2105/AJPH.2020.305945. Epub 2020 Sep 24. PMID: 32970452; PMCID: PMC7661983.
Copy Download .nbib Format: NLM
Clinical features and genetic risk of demyelination following anti-TNF treatment.

Journal of Crohn's & colitis

Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, Coles AJ, Silverberg MS, Irving PM, Chung-Faye G, Silber E, Cummings F, Lytvyak E, Andersen V, Wood AR, Tyrrell J, Beaumont RN, Weedon MN, Kennedy NA, Spiers A, Harrower T, Goodhand JR, Ahmad T.
PMID: 32497177
J Crohns Colitis. 2020 Jun 04; doi: 10.1093/ecco-jcc/jjaa104. Epub 2020 Jun 04.

BACKGROUND: Anti-TNF exposure has been linked to demyelination events. We sought to describe the clinical features of demyelination events following anti-TNF treatment and test whether affected patients were genetically predisposed to multiple sclerosis (MS).METHODS: We conducted a case-control study...

Cite
Lin S, Green HD, Hendy P, et al. Clinical features and genetic risk of demyelination following anti-TNF treatment. J Crohns Colitis. 2020;doi: 10.1093/ecco-jcc/jjaa104.
Lin, S., Green, H. D., Hendy, P., Heerasing, N. M., Chanchlani, N., Hamilton, B., Walker, G. J., Heap, G. A., Hobart, J., Martin, R. J., Coles, A. J., Silverberg, M. S., Irving, P. M., Chung-Faye, G., Silber, E., Cummings, F., Lytvyak, E., Andersen, V., Wood, A. R., Tyrrell, J., Beaumont, R. N., Weedon, M. N., Kennedy, N. A., Spiers, A., Harrower, T., Goodhand, J. R., Ahmad, T. (2020). Clinical features and genetic risk of demyelination following anti-TNF treatment. Journal of Crohn's & colitis, . https://doi.org/10.1093/ecco-jcc/jjaa104
Lin, Simeng, et al. "Clinical features and genetic risk of demyelination following anti-TNF treatment." Journal of Crohn's & colitis vol. (2020). doi: https://doi.org/10.1093/ecco-jcc/jjaa104
Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, Coles AJ, Silverberg MS, Irving PM, Chung-Faye G, Silber E, Cummings F, Lytvyak E, Andersen V, Wood AR, Tyrrell J, Beaumont RN, Weedon MN, Kennedy NA, Spiers A, Harrower T, Goodhand JR, Ahmad T. Clinical features and genetic risk of demyelination following anti-TNF treatment. J Crohns Colitis. 2020 Jun 04; doi: 10.1093/ecco-jcc/jjaa104. Epub 2020 Jun 04. PMID: 32497177.
Copy Download .nbib Format: NLM
Thrombotic Microangiopathy and Venous Thrombosis in a Patient With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

Cureus

Duong K, Etienne S, Collazo-Maldonado R, Lytvak I.
PMID: 33391903
Cureus. 2020 Nov 23;12(11):e11665. doi: 10.7759/cureus.11665.

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic pauci-immune small vessel vasculitis. Its various presentations make AAV diagnosis challenging. Here, we present a case of AAV with thrombotic microangiopathy (TMA) and deep venous thrombosis (DVT). An 82-year-old Hispanic...

Cite
Duong K, Etienne S, Collazo-Maldonado R, et al. Thrombotic Microangiopathy and Venous Thrombosis in a Patient With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Cureus. 2020;12(11):e11665doi: 10.7759/cureus.11665.
Duong, K., Etienne, S., Collazo-Maldonado, R., & Lytvak, I. (2020). Thrombotic Microangiopathy and Venous Thrombosis in a Patient With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Cureus, 12(11), e11665. https://doi.org/10.7759/cureus.11665
Duong, Khanh, et al. "Thrombotic Microangiopathy and Venous Thrombosis in a Patient With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis." Cureus vol. 12,11 (2020): e11665. doi: https://doi.org/10.7759/cureus.11665
Duong K, Etienne S, Collazo-Maldonado R, Lytvak I. Thrombotic Microangiopathy and Venous Thrombosis in a Patient With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Cureus. 2020 Nov 23;12(11):e11665. doi: 10.7759/cureus.11665. PMID: 33391903; PMCID: PMC7769722.
Copy Download .nbib Format: NLM
Severe Erosive Esophagitis Secondary to Gastric Outlet Obstruction Related to Pseudomyxoma Peritonei.

ACG case reports journal

Braun DS, Bushe B, Lytvak I, Kedia P.
PMID: 33447626
ACG Case Rep J. 2021 Jan 08;8(1):e00505. doi: 10.14309/crj.0000000000000505. eCollection 2021 Jan.

Pseudomyxoma peritonei (PMP) is a rare clinical condition characterized by a mucin-producing tumor. PMP tumor cells migrate to abdominal and pelvic sites, eventually enveloping intra-abdominal organs and compressing the gastrointestinal tract. Patients with PMP are often asymptomatic in early...

Cite
Braun DS, Bushe B, Lytvak I, et al. Severe Erosive Esophagitis Secondary to Gastric Outlet Obstruction Related to Pseudomyxoma Peritonei. ACG Case Rep J. 2021;8(1):e00505doi: 10.14309/crj.0000000000000505.
Braun, D. S., Bushe, B., Lytvak, I., & Kedia, P. (2021). Severe Erosive Esophagitis Secondary to Gastric Outlet Obstruction Related to Pseudomyxoma Peritonei. ACG case reports journal, 8(1), e00505. https://doi.org/10.14309/crj.0000000000000505
Braun, David S, et al. "Severe Erosive Esophagitis Secondary to Gastric Outlet Obstruction Related to Pseudomyxoma Peritonei." ACG case reports journal vol. 8,1 (2021): e00505. doi: https://doi.org/10.14309/crj.0000000000000505
Braun DS, Bushe B, Lytvak I, Kedia P. Severe Erosive Esophagitis Secondary to Gastric Outlet Obstruction Related to Pseudomyxoma Peritonei. ACG Case Rep J. 2021 Jan 08;8(1):e00505. doi: 10.14309/crj.0000000000000505. eCollection 2021 Jan. PMID: 33447626; PMCID: PMC7803678.
Copy Download .nbib Format: NLM
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.

Liver international : official journal of the International Association for the Study of the Liver

Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S.
PMID: 34846800
Liver Int. 2021 Nov 30; doi: 10.1111/liv.15121. Epub 2021 Nov 30.

BACKGROUND: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH).PATIENTS AND METHODS: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes...

Cite
Efe C, Lammert C, Taşçılar K, et al. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver Int. 2021;doi: 10.1111/liv.15121.
Efe, C., Lammert, C., Taşçılar, K., Dhanasekaran, R., Ebik, B., Higuera-de la Tijera, F., Calışkan, A. R., Peralta, M., Gerussi, A., Massoumi, H., Catana, A. M., Purnak, T., Rigamonti, C., Aldana, A. J. G., Khakoo, N., Nazal, L., Frager, S., Demir, N., Irak, K., Melekoğlu-Ellik, Z., Kacmaz, H., Balaban, Y., Atay, K., Eren, F., Alvares-da-Silva, M. R., Cristoferi, L., Urzua, �. �., Eşkazan, T., Magro, B., Snijders, R., Barutçu, S., Lytvyak, E., Zazueta, G. M., Demirezer-Bolat, A., Aydın, M., Heurgue-Berlot, A., De Martin, E., Ekin, N., Yıldırım, S., Yavuz, A., Bıyık, M., Narro, G. C., Kıyıcı, M., Akyıldız, M., Kahramanoğlu-Aksoy, E., Vincent, M., Carr, R. M., Günşar, F., Reyes, E. C., Harputluoğlu, M., Aloman, C., Gatselis, N. K., Üstündağ, Y., Brahm, J., Vargas, N. C. E., Güzelbulut, F., Garcia, S. R., Aguirre, J., Anders, M., Ratusnu, N., Hatemi, I., Mendizabal, M., Floreani, A., Fagiuoli, S., Silva, M., Idilman, R., Satapathy, S. K., Silveira, M., Drenth, J. P. H., Dalekos, G. N., N Assis, D., Björnsson, E., Boyer, J. L., Yoshida, E. M., Invernizzi, P., Levy, C., Montano-Loza, A. J., Schiano, T. D., Ridruejo, E., & Wahlin, S. (2021). Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver international : official journal of the International Association for the Study of the Liver, . https://doi.org/10.1111/liv.15121
Efe, Cumali, et al. "Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis." Liver international : official journal of the International Association for the Study of the Liver vol. (2021). doi: https://doi.org/10.1111/liv.15121
Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver Int. 2021 Nov 30; doi: 10.1111/liv.15121. Epub 2021 Nov 30. PMID: 34846800.
Copy Download .nbib Format: NLM
Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis.

Liver international : official journal of the International Association for the Study of the Liver

Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Miranda Zazueta G, Demirezer Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Castro Narro G, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Cerda Reyes E, Harputoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Chris Escajadillo Vargas N, Güzelbulut F, Ruiz Garcia S, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S.
PMID: 34846800
Liver Int. 2021 Nov 30; doi: 10.1111/liv.15121. Epub 2021 Nov 30.

BACKGROUND: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH).PATIENTS AND METHODS: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes...

Cite
Efe C, Lammert C, Taşçılar K, et al. Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis. Liver Int. 2021;doi: 10.1111/liv.15121.
Efe, C., Lammert, C., Taşçılar, K., Dhanasekaran, R., Ebik, B., Higuera-de la Tijera, F., Calışkan, A. R., Peralta, M., Gerussi, A., Massoumi, H., Catana, A. M., Purnak, T., Rigamonti, C., Gomez Aldana, A. J., Khakoo, N., Nazal, L., Frager, S., Demir, N., Irak, K., Melekoğlu Ellik, Z., Kacmaz, H., Balaban, Y., Atay, K., Eren, F., Alvares-da-Silva, M. R., Cristoferi, L., Urzua, �. �., Eşkazan, T., Magro, B., Snijders, R., Barutçu, S., Lytvyak, E., Miranda Zazueta, G., Demirezer Bolat, A., Aydın, M., Heurgue-Berlot, A., De Martin, E., Ekin, N., Yıldırım, S., Yavuz, A., Bıyık, M., Castro Narro, G., Kıyıcı, M., Akyıldız, M., Kahramanoğlu-Aksoy, E., Vincent, M., Carr, R. M., Günşar, F., Cerda Reyes, E., Harputoğlu, M., Aloman, C., Gatselis, N. K., Üstündağ, Y., Brahm, J., Chris Escajadillo Vargas, N., Güzelbulut, F., Ruiz Garcia, S., Aguirre, J., Anders, M., Ratusnu, N., Hatemi, I., Mendizabal, M., Floreani, A., Fagiuoli, S., Silva, M., Idilman, R., Satapathy, S. K., Silveira, M., Drenth, J. P. H., Dalekos, G. N., Assis, D. N., Björnsson, E., Boyer, J. L., Yoshida, E. M., Invernizzi, P., Levy, C., Montano-Loza, A. J., Schiano, T. D., Ridruejo, E., & Wahlin, S. (2021). Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis. Liver international : official journal of the International Association for the Study of the Liver, . https://doi.org/10.1111/liv.15121
Efe, Cumali, et al. "Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis." Liver international : official journal of the International Association for the Study of the Liver vol. (2021). doi: https://doi.org/10.1111/liv.15121
Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Miranda Zazueta G, Demirezer Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Castro Narro G, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Cerda Reyes E, Harputoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Chris Escajadillo Vargas N, Güzelbulut F, Ruiz Garcia S, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis. Liver Int. 2021 Nov 30; doi: 10.1111/liv.15121. Epub 2021 Nov 30. PMID: 34846800.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries